Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

In the last week, the market has been flat, but over the past 12 months, it has risen by 12%, with earnings forecast to grow by 14% annually. While traditional investments often focus on established ...

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock soar by 240% after announcing highly encouraging results from its Phase ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the ...

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC: London, UK Friday, May 30, 2025, 15:00 Hrs [IST] ...

Shares of Spero Therapeutics gained after the company and GSK ended their trial for a treatment for complicated urinary tract infections early after it met its primary endpoint. The stock more than ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

Major health sector news includes GSK and Spero stopping a UTI drug trial due to early success, Brazil's bird flu cases and ...

Spero Therapeutics (SPRO) stock jumps as GSK (GSK) partnered oral UTI treatment, tebipenem HBr, succeeds in a pivotal Phase 3 ...

Recent health news highlights include GSK and Spero halting a UTI drug trial after achieving success, Sanofi exploring ...